FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Related Keywords

United States ,Uganda ,Sudan ,Axel Lehrer ,Oreola Donini ,Our Public Health Solutions ,Us Congress ,Exchange Commission ,Soligenix Inc ,Twitter ,Drug Administration ,Defense Threat Reduction Agency ,National Institute Of Allergy ,Nasdaq ,Centers For Disease ,Biomedical Advanced Research ,Prnewswire Soligenix Inc ,Development Authority ,Linkedin ,University Of Hawai ,Provides Suvax ,Heat Stable Vaccine Seven Years ,Exclusivity Upon ,Orphan Products Development ,Drug Act ,Biologics License Application ,Senior Vice President ,Chief Scientific Officer ,Sudan Virus Disease ,Sudan Ebola ,Generally Regarded ,Ebola Virus Disease ,Marburg Virus Disease ,Disease Control ,Sudan Virus ,Public Health Solutions ,National Institute ,Infectious Diseases ,Project Bioshield ,Priority Review Voucher ,Soligenix ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Fda Approval ,